Member Info for biffbaffboff

So, I can't say I am not a little confused. Wasn't it in January that the "directors believe it is no longer in shareholders' interests to embark on a Phase 2 clinical trial of gallium maltolate as previously intended. The financial and operational resources would be better employed to concentrate upon nearer-term commercial objectives of our imaging solutions."

Are we now embarking on a Phase 2 clinical trial of gallium maltolate as previously intended? Or am I missing something?

One of my other investments:

".... invites private shareholders for drinks and Q&A in central London on ...."

"The occasion is a chance to discuss how ####### is progressing these projects towards meaningful value....."

We wait for Tim's invite!

"Why are so many holders still here if you hate the company so much. It has finally gaining traction towards cashflow and is priced to fail which at this stage makes no sense to me."

Many of us don't hate the company, and being 80% - 90% down, many of us have decided that it isn't worth it to sell up now. What we want to see is the BOD running the company properly. It is our money that has funded other pursuits whilst the core of the business still isn't breaking even. Concentrate on that for a while. Release some good figures showing a profit. Raise the SP., then ask for funds with a prospective outlook to progress the company. At the moment, it feels like they need funds to keep the lights on, but are stringing us along with "the Board is confident the Group is entering a period of revenue acceleration. Our expectation of progress towards profitability in 2026 is unchanged."

Show us the figures then!

Is the German agreement still an agreement in principle.? Still risks I guess.

I will be voting against this resolution. They need to focus on the core business.

"The Group meets its day to day working capital requirements through its revenue generating cash flows, discrete fund raises and the issue of convertible loan notes. No such fund raises and issues of convertible loans are planned at this time as these are not currently required. "

Therefore, get the SP above 1p before asking for any more raises.

AI Overview:

There is no clinical difference between the terms immune normaliser (UK spelling) and immunonormalizer (US spelling). Both are used interchangeably in modern immuno-oncology and autoimmune therapy to describe treatments designed to restore healthy immune function rather than over-stimulating or broadly suppressing it.

Do you not think if they had positive news it would warrant a RNS!?

Well, yes, that's the frustration, hasn't been anything positive for a while now. Even a positive outlook would be welcome.

Maybe we'll get something positive with the interims.

The lack of news, or any updates is frustrating.

Only another 2.8% and IBAI will be on the top of the riser board. I might be buy a few more just to help it get there. Average down!

I don't profess to understand it all, but It does raise questions around the recent Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma, subsequently discussed as "sponsored" and how a completely different entity can now do another Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma but in pediatrics.

I think you might be right. There are blurred lines between Michael and Kathleen with regards to Imaging biometrics and the MCW. If we don't actually own the rights, but are only licensing the use of, then this is only ever going to be worth what we can sell, rather than the asset itself. And it's proving more difficult to increase sales.

The website certailny suggests we do:

"Our flagship product, IB Neuro™"

I will be voting against this resolution. They need to focus on the core business.

"The Group meets its day to day working capital requirements through its revenue generating cash flows, discrete fund raises and the issue of convertible loan notes. No such fund raises and issues of convertible loans are planned at this time as these are not currently required. "

Therefore, get the SP above 1p before asking for any more raises.

Agreed, now is a good time to take a position. Ducks are lining up.

Very little news about this since announcement in December:

"FirstGroup has taken over operation of the London Overground as its eight-year concessions begins.

The operator, though its subsidiary First Rail London Limited (FRLL), took over from Arriva in the early hours of May 3 which had operated the network since November 2016.

Transport for London awarded FRLL an eight-year contract in December, with an optional two-year extension.

FRLL will introduce extra services on the Mildmay (Richmond/Clapham Junction-Stratford) and Windrush (West Croydon/Clapham Junction/Crystal Palace/New Cross-Highbury & Islington)."

Truetide up by 22%. Is something bubbling over there related to over here?

Still says it's in suspension, not RNS yet to say otherwise, but 2 trades have shown up. Hopefully sorted tomorrow latest (they did say this week).

"Your directors are confident that 2026 will be a year of revenue acceleration and bottom-line delivery and believe that the current share price does not fully reflect the progress made and the near-term growth opportunities ahead."

So, we are expecting results today? As previously discussed, has always been so, so unless there is a loophole.... Don't see a reason to hold off, unless other news is due which might help value. Not expecting anything close to good in the meantime, otherwise feel there would have been a leak and a few buys this morning/yesterday.